Abstract
The antiemetic efficacy of granisetron, ondansetron and tropisetron was evaluated in patients treated with cisplatin-Adriamycin (CDP/ADM) and ifosfamide (IFO) by continuous infusion (CI). In all, 90 patients with osteosarcoma were randomly assigned to receive granisetron (2 mg/m2), or ondansetron (5.3 mg/m2), or tropisetron (3.3 mg/m2) plus dexamethasone 8 mg/m2. Chemotherapy consisted of CDP (120 mg/m2, 48-h CI) followed by ADM (75 mg/m2, 24-h CI) and then, in the second cycle, delivered 3 weeks later, IFO 15 g/m2 (120-h CI). Complete protection (CP) from emesis was obtained on 59% of the 717 days of treatment, without significant differences among the three study drugs. A significantly higher rate of CP was obtained during chemotherapy with IFO than with CDP/ADM (69% vs 44%; P
Original language | English |
---|---|
Pages (from-to) | 131-133 |
Number of pages | 3 |
Journal | Supportive Care in Cancer |
Volume | 8 |
Issue number | 2 |
Publication status | Published - Mar 2000 |
Keywords
- Continuous infusion
- Emesis
- Granisetron
- Ondansetron
- Tropisetron
ASJC Scopus subject areas
- Oncology
- Nursing(all)